ArticleExperimental and therapeutic medicine2026
Mitochondrial autophagy promotion contributes to the protective effects of BYHWD glycoside-enriched fraction against OGD/R-induced injury in H9C2 cells.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial ischemia-reperfusion injury is a major cause of mortality among patients with cardiovascular diseases and critically ill individuals. Its pathogenesis is complex and effective preventive or therapeutic strategies remain limited. Buyang Huanwu Decoction (BYHWD) is a classical Traditional Chinese Medicine formula used to tonify deficiency and promote blood circulation and is widely applied in the treatment of cardiovascular and cerebrovascular disorders. The total glycosides extracted from BYHWD, which mainly comprise astragaloside IV, paeoniflorin and amygdalin, represent its key bioactive components. Notably, the extract used is a glycoside-enriched fraction, in which astragaloside IV, paeoniflorin and amygdalin are the three major quantified components, rather than a pure mixture of these three compounds. In the present study, an H9C2 cell model of ischemia-reperfusion injury was established by 21 h of hypoxia followed by 6 h of reoxygenation to evaluate the cardioprotective effects of BYHWD glycosides. Autophagy and reactive oxygen species levels were analyzed by flow cytometry, while malondialdehyde and superoxide dismutase activities were measured using appropriate assay kits. Mitochondrial membrane potential changes were observed by fluorescence microscopy. The expression of PINK1 and Parkin pathway-associated proteins and genes was examined by western blotting and reverse transcription-quantitative PCR. Overall, BYHWD glycosides significantly reduced oxidative damage in H9C2 cells and protected cardiomyocytes from reperfusion injury, potentially by promoting mitochondrial autophagy. These protective effects may therefore be associated with regulation of the PINK1/Parkin-mediated mitochondrial autophagy pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.